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Abstract 
Background: Completion of HIV life cycle in CD4+ T lymphocytes needs cell activation. We recently reported that 
treatment of resting CD4+ T lymphocytes with exosomes produced by HIV-1 infected cells induces cell activation 
and susceptibility to HIV replication. Here, we present data regarding the effects of these exosomes on cells latently 
infected with HIV-1.
Results: HIV-1 latently infecting U937-derived U1 cells was activated upon challenge with exosomes purified from 
the supernatant of U937 cells chronically infected with HIV-1. This effect was no more detectable when exosomes 
from cells infected with HIV-1 strains either nef-deleted or expressing a functionally defective Nef were used, indicat-
ing that Nef is the viral determinant of exosome-induced HIV-1 activation. Treatment with either TAPI-2, i.e., a specific 
inhibitor of the pro-TNFα-processing ADAM17 enzyme, or anti-TNFα Abs abolished HIV-1 activation. Hence, similar to 
what previously demonstrated for the exosome-mediated activation of uninfected CD4+ T lymphocytes, the Nef-
ADAM17-TNFα axis is part of the mechanism of latent HIV-1 activation. It is noteworthy that these observations have 
been reproduced using: (1) primary CD4+ T lymphocytes latently infected with HIV-1; (2) exosomes from both primary 
CD4+ T lymphocytes and macrophages acutely infected with HIV-1; (3) co-cultures of HIV-1 acutely infected CD4+ 
T lymphocytes and autologous lymphocytes latently infected with HIV-1, and (4) exosomes from cells expressing a 
defective HIV-1.
Conclusions: Our results strongly suggest that latent HIV-1 can be activated by TNFα released by cells upon inges-
tion of exosomes released by infected cells, and that this effect depends on the activity of exosome-associated 
ADAM17. These pieces of evidence shed new light on the mechanism of HIV reactivation in latent reservoirs, and 
might also be relevant to design new therapeutic interventions focused on HIV eradication.
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Background
HIV infection is efficiently counteracted by combination 
anti-retroviral therapy (cART) which, despite prevent-
ing disease progression, does not eradicate virus infec-
tion which persists in a latent form. The latent reservoir 
is generated by virus entry in activated CD4+ T lym-
phocytes committed to return to a resting state [1], even 
though also resting CD4+ T lymphocytes can be latently 
infected [2]. Thus, one may assume that HIV reservoir is 
prevalently composed by memory CD4+ T lymphocytes. 
Therapy interruption leads to viral rebound, which has 
been observed also after a long time from cART discon-
tinuation [3]. This event is most likely the consequence of 
the extended half-life of HIV reservoir (about 44 months) 
[4], which can also expand through homeostatic prolif-
eration [5], i.e. an IL-7-dependent mechanism allowing 
central memory CD4+ T lymphocytes to proliferate with-
out cell differentiation/activation.
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HIV-1 infected cells release nanovesicles in the form of 
viral particles and non-viral vesicles including exosomes. 
The latter are lipid bilayer vesicles of 50–100 nm, which 
form intracellularly upon inward invagination of endo-
some membranes [6]. These intraluminal vesicles become 
part of multivesicular bodies (MVBs) and either undergo 
lysosomal degradation, or are released into extra-cellu-
lar space upon fusion of MVBs with plasma membrane. 
Nanovesicles similar to exosomes can be released also 
through direct extrusion of plasma membrane [7]. In 
some instances methods of purification and analysis can-
not distinguish between endosome-produced nanovesi-
cles and vesicles of similar dimensions but released from 
plasma membrane. For the sake of clarity, these nanovesi-
cles are here defined as exosomes irrespectively of their 
biogenesis.
Budding of HIV and related lenti- and retroviruses 
is preceded by interaction with a number of cell factors 
involved in exosome biogenesis such as Alix, Tsg101, 
and several other components of the endosomal sorting 
complex required for transport (ESCRT) [8]. The conver-
gence of exosome and HIV biogenesis implies the possi-
bility that viral products can be uploaded in exosomes as 
observed in the case of HIV-1 Gag [9] and Nef [10, 11].
Exosomes are part of the intercellular communication 
network [12]. They incorporate messenger RNAs, micro-
RNAs, and proteins which can be functional in tar-
get cells [13]. These evidences posed the question over 
whether or not biologically active molecules uploaded 
in exosomes from HIV infected cells can influence inter-
cellular communication, and the possible relevance 
of this event in HIV pathogenesis. On this subject, we 
recently provided evidence that primary CD4+ T lym-
phocytes infected with HIV-1 release exosomes which 
activate quiescent human primary CD4+ T lympho-
cytes which in turn become permissive to HIV-1 infec-
tion [14, 15]. The key event for the activation of resting 
lymphocytes is the uploading of activated ADAM17 in 
exosomes released by infected cells. ADAM17 belongs 
to the family of ADAM (a disintegrin and metallopro-
tease) enzymes [16]. It is a multi-domain, transmem-
brane, Zn2+-dependent proteinase whose inactive form 
is cleaved by furin in the trans-Golgi network. The most 
studied function of ADAM17 (also known as TACE, 
TNFα-converting enzyme) is the processing of pro-
TNFα into its active form. Considering that TNFα is a 
pleiotropic cytokine, uploading of activated ADAM17 
in exosomes could have broad consequences in many 
aspects of HIV-induced pathogenesis.
Here, we provide evidence that exosomes from cells 
expressing either replication-competent or non-pro-
ducer HIV-1 activate latent HIV-1 through a mechanism 
depending on both ADAM17 and TNFα.
Results
Purification of exosomes from U937 cell lines chronically 
infected with HIV‑1
Exosomes produced by HIV-1 infected cells can induce 
cell activation in target CD4+ T lymphocytes [14, 15]. 
Since we proved that TNFα is part of the underlying 
mechanism, we were interested in assessing possible 
effects of exosomes released by HIV-1 infected cells on 
latent HIV-1, which has been reported to be activated 
by this cytokine [17]. To this end, the availability of large 
amounts of pure exosomes was mandatory. Most con-
veniently, they can be obtained from supernatants of cell 
lines stably expressing wild-type HIV-1. However, basi-
cally all HIV-1 chronically infected cell lines so far iso-
lated express HIV-1 genomes defective for one or more 
genes. In particular, the anti-cellular effects induced by 
the stable expression of Nef [18–20] hamper the isolation 
of cell lines stably infected with Nef-expressing HIV-1. 
To overcome this hindrance, we isolated HIV-1 chroni-
cally infected cells starting from the previously described 
U937 cell lines stably transfected with either wild-type 
(wt) HIV-1 Nef or mutants thereof fused at their C-ter-
minus with the estrogen receptor (ER) [21]. The ER 
domain keeps Nef in an inactive state through a steric 
hindrance which is relieved upon binding with the estro-
gen antagonist 4-hydroxytamoxifen (HT). In detail, U937 
cells stably transfected with vectors expressing ER either 
alone, fused with wt Nef, or with the NefG2A mutant 
defective for ADAM17 uploading in exosomes [14], were 
infected with ΔnefNL4-3 HIV-1. Infected cell cultures 
were carried out in the absence of HT until the percent-
age of infected cells was >75  %, which remained stable 
over time. The amount of HIV-1 particles released by 
the three cell lines did not change significantly after HT 
stimulation (Fig. 1a). Consistently, no apparent variations 
in the expression of HIV-1 products were seen after HT 
treatment (Fig. 1b), except for a slight increase of Nef-ER 
possibly due to an improved stability of the fusion prod-
ucts [22]. As assessed by intracytoplasmic FACS analysis, 
the striking majority of both U937 Δnef HIV-1/wt Nef 
and U937 Δnef HIV-1/NefG2A cells co-expressed both 
Gag and Nef products after HT treatment (Fig. 1c).
For exosome purification, parental U937 as well as the 
different HIV-1 chronically infected cell lines were treated 
with HT and, 48 h later, supernatants were harvested and 
processed by differential centrifugations. The resulting 
nanovesicle pellets were then loaded on 6–18  % discon-
tinuous iodixanol gradients to separate exosomes from 
HIV-1 particles. Gradient fractions were then assayed in 
terms of acetylcholinesterase (AchE) activity (i.e., a clas-
sical exosome marker) [23] for exosome detection, and, 
whenever relevant, HIV-1 Gag products (Fig. 2). Nanoves-
icle preparations recovered from AchE strongly positive 
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fractions were further characterized in terms of presence 
of both CD63 (i.e., a tetraspanin typically associated with 
exosomes) [24], and monosialotetrahexosylganglioside 
(GM1), i.e., a component of nanovesicle-associated lipid 
rafts detectable through binding with the subunit B of 
cholera toxin (CTX-B) (Fig. 2, insets) [25].
HIV‑1 latently infecting U1 cells is activated by exosomes 
from HIV‑1 infected cells
We investigated possible virologic effects of exosomes 
from HIV-1 infected cells on HIV-1 latently infected 
cells. In a first instance, we analyzed the effects on U1 
cells [26], i.e., U937-derived cells with two inactive 
HIV-1 proviruses integrated which express mutated/
inactive tat. In particular, tat from one HIV-1 provirus 
lacks the ATG start codon, whereas the other expresses 
a Tat protein whose functions are heavily compromised 
by the H to L substitution at the amino acid 13 [27]. 
Treatment of U1 cells with either wild-type Tat, tumor 
necrosis factor (TNF)α, phorbol myristate acetate 


































Fig. 1 Characterization of HIV-1 chronically infected U937-based cell lines expressing Nef in a regulatable way. a Determination of viral release 
from HIV-1 chronically infected U937-based cell lines by HIV-1 CAp24 ELISA. Cultures of 106 cells/mL of U937 cells either uninfected or chronically 
infected with Δnef HIV-1, the latter stably transfected with vectors expressing either ER alone (U937 Δnef HIV-1), ER fused with wt Nef (U937 Δnef 
HIV-1/wt Nef ), or ER fused with the Nef G2A mutant (U937 Δnef HIV-1/NefG2A), were carried out for 48 h with either HT or equal volume of vehicle. 
Afterwards, supernatants were harvested, clarified, and viral contents measured in terms of concentration of CAp24. Shown are the mean values 
+SD as calculated from duplicate conditions run in seven independent experiments. Nd: not detectable. b Western blot analysis for expression 
of HIV-1 related products in the HIV-1 chronically infected U937 cell lines either untreated (−) or treated (+) with HT for 48 h. Cell lysates from 
the U937-based cell lines were resolved in 12 % SDS-PAGE and probed for Gag, Env (upper panel), and Nef expression (middle panel). Signals were 
normalized by β-actin detection (lower panel). On the right of each panel, molecular weight markers are given in kilodaltons (kDa). On the left, 
migrations of relevant products are indicated. The results are representative of five independent experiments. c FACS analysis for the expression of 
both Gag and Nef products. The different U937-based cell lines were incubated for 48 h with HT or equal volume of vehicle, then permeabilized and 
labeled with both anti-Gag and—Nef mAbs. Percentages of events are reported in the respective quadrants. The results are representative of two 
independent experiments
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We treated U1 cells with different amounts (i.e., from 
30 to 120 μU of AchE activity) of exosomes purified from 
HT-treated U937 cells expressing either ER alone, both 
Δnef HIV-1 and ER, Δnef HIV-1 and wtNef-ER, or Δnef 
HIV-1 and NefG2A-ER. Only the challenge with exosomes 
from HIV-1 infected cells expressing wt Nef induced 
activation of latent HIV-1 (Fig.  3a). The effect appeared 
to be dose-dependent, and required the expression of a 
functional Nef in exosome-producing cells.
Nef induces exosome uploading of activated ADAM17, 
which, once ingested by target cells, leads to the release 
of mature TNFα [14, 15, 29]. To assess whether a similar 
mechanism was at the basis of the exosome-dependent 
activation of latent HIV-1 in U1 cells, we first meas-
ured the amount of activated ADAM17 in exosome 
preparations. As expected, exosomes produced by cells 
expressing wtNef associated with much higher amounts 
of activated ADAM17 than those from the other cell 
lines assayed (Fig.  3b). Afterwards, either TAPI-2 (i.e., 
a specific inhibitor of ADAM17) [30] or neutralizing 
anti-TNFα Abs were added to U1 cell cultures immedi-
ately after exosome challenge. Both treatments led to 
a sharp decrease of the exosome-induced activation of 
latent HIV-1 (Fig.  3c), thus strongly suggesting that the 
phenomenon we observed was driven by a mechanism 
similar to that previously described for uninfected qui-
escent CD4+ T lymphocytes [14, 15]. Of importance, 
all exosome preparations we used were found devoid of 
detectable amounts of TNFα (not shown).
Together, these results represent a preliminary indi-
cation that latent HIV-1 infection can be activated by 
exosomes from HIV-1 productively infected cells.
Set up of a system of HIV‑1 latent infection in unstimulated 
primary CD4+ T lymphocytes
Next, we tried to extend our results to a more physi-
ologic context of HIV-1 latent infection. Different proto-
cols aimed at recovering HIV-1 latently infected primary 
cells have been described [31–37], and recently com-




















































































































Fig. 2 Purification and characterization of exosomes from parental and HIV-1 chronically infected U937 cells expressing Nef in a regulatable way. 
AchE activity and, for HIV-1 infected cells only, HIV-1 Gag CAp24 contents were measured in fractions from 6 to 18 % iodixanol gradients loaded 
with vesicles obtained by differential centrifugations of supernatants from a U937, b U937 ΔnefHIV-1, c U937 ΔnefHIV-1/wtNef, and d U937 
ΔnefHIV-1/NefG2A cells after treatment with HT for 48 h. In the insets, shown are FACS analyses for the presence of both GM1 and CD63 in nanovesi-
cles recovered from pools of AchE positive fractions of iodixanol gradients. Vesicles were bound to aldehyde/sulfate latex beads and then labeled 
with FITC-conjugated CTX-B and PE-conjugated anti-CD63 mAb. The results are representative of two independent experiments
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by Greene and coll. [31] with few modifications. In 
detail, CD4+ T lymphocytes were isolated from periph-
eral blood mononuclear cells (PBMCs) of healthy donors 
by negative immunomagnetic selection. Untouched 
cells were challenged by spinoculation with ΔenvHIV-1 
pseudotyped with vesicular stomatitis virus (VSV)-G 
protein in the presence or not of 10 μM azidothymidine 
(AZT), and 48  h later extensively washed. We observed 
that after additional 24  h viral replication remained 































































Fig. 3 HIV-1 latently infecting U1 cells is activated upon challenge with exosomes from HIV-1 infected cells in a Nef-, TNFα-, and ADAM17-depend-
ent manner. a Different amounts of exosomes (i.e., from 30 to 120 μU of AchE activity) purified from supernatants of the indicated cell lines were 
used to challenge 5 × 104 U1 cells in U-bottom 96 well plates. After 24 h, the cells were extensively washed, and the amount of released HIV-1 was 
measured in terms of CAp24 concentration in the supernatants, after additional 24 h. As a control, cells were left untreated (Ctrl) or treated with 
100 ng/mL of recombinant TNFα. The results are the mean values + SD from five independent experiments carried out with duplicates. *p < 0.05. b 
ADAM17 activity detected in 1 mU of exosomes purified from the supernatants of the indicated U937-derived cell lines. Shown are mean amounts 
of active ADAM17 + SD detected in quadruplicate samples from a representative exosome preparation from each cell line. c Effects of TAPI-2 and 
anti-TNFα on the activation of latent HIV-1 induced by exosomes from HIV-1 expressing cells. U1 cells (5 × 104/condition) were challenged with 
100 μU of exosomes from HIV-1 infected cells expressing wt Nef. Then, cells were left untreated or incubated in the presence of either 1 μM TAPI-2, 
160 ng/mL of anti-TNFα neutralizing antibodies, or equivalent amounts of unrelated, isotype-specific IgGs. As a control, cells were treated with 
100 ng/mL of recombinant TNFα in the presence or not of the anti-TNFα neutralizing antibodies. After 24 h, cells from all conditions were exten-
sively washed, re-seeded in the appropriate conditions, and the amount of HIV-1 released in supernatants was measured as CAp24 concentration 
after additional 24 h. The results are the mean values + SD from three independent experiments carried out with duplicates. *p < 0.05
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assessment of CAp24 in both cells (Fig.  4a) and super-
natants (not shown). Treatment of challenged cultures 
with different amounts of PMA led to the appearance of 
3–8 % of cells expressing HIV-1 within 24 h (Fig. 4b). The 
percentage of infected cells then decreased (not shown) 
most likely as a consequence of the cytotoxic effect of 
HIV-1 which, in view of its env defectiveness, cannot 
spread in bystander activated cells.
HIV-1 activation did not take place in PMA stimulated 
CD4+ T lymphocytes treated with AZT before infection 
(Fig. 4b), demonstrating that the results from FACS anal-
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Fig. 4 Set up of a system of HIV-1 latent infection. Untouched CD4+ T lymphocytes were purified from PBMCs of healthy donors and challenged 
by spinoculation with (VSV-G) Δenv HIV-1 in the presence or not of AZT. As a control, conditions with unchallenged CD4+ T lymphocytes (Ctrl) were 
also run. After 48 h, cells were extensively washed and then left in culture for additional 24 h. a Intracytoplasmic CAp24 FACS analysis of CD4+ T 
lymphocytes 72 h post-infection. The results are the mean values + SD from nine independent experiments carried out with duplicates. b Intracy-
toplasmic CAp24 FACS analysis of CD4+ T lymphocytes which, 72 h post-infection, were either activated for 24 h by the indicated doses of PMA+ 
0.5 μg/μL of ionomycin (PMA) or left untreated. Ctrl: uninfected CD4+ T lymphocytes. The results are the mean values + SD from three independent 
experiments carried out with duplicates. In the bottom panels, shown are representative raw results obtained by the intracytoplasmic CAp24 FACS 
analysis of CD4+ T lymphocytes either uninfected (Ctrl), or latently infected with (VSV-G) Δenv HIV-1 in the presence or not of AZT, and treated for 
24 h with PMA + ionomycin
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Exosomes from HIV‑1 infected cells activate latent HIV‑1 
in primary CD4+ T lymphocytes
The here above described experimental system 
was instrumental to determine possible effects 
of exosomes from HIV-1 infected cells on HIV-1 
latently infecting primary lymphocytes. To this 
aim, untouched CD4+ T lymphocytes from four dif-
ferent healthy donors were infected with (VSV-
G) ΔenvHIV-1 in the presence or not of AZT. After 
3  days, the percentage of cells actively expressing 
HIV-1 was assessed by intracellular Gag-specific 
FACS analysis (Fig.  5a). At this time, the absence 
of detectable Gag-expressing cells in the infected 
cell population was a mandatory condition to pro-
ceed with the exosome challenge. Purified exosomes 
(100 μU) from U937, U937 Δnef HIV-1 and U937 Δnef 
HIV-1/wtNef cells were used to challenge the cul-
tures of HIV-1 latently infected CD4+ T lymphocytes, 
whose percentages of HIV-1 expressing cells were 
measured 24  h later. As shown in Fig.  5b, CD4+ T 
lymphocytes expressing Gag proteins were detectable 
only after challenge with exosomes from Nef express-
ing HIV-1 infected cells. As expected, no Gag-positive 
CD4+ T lymphocytes were detected when cells were 
treated with AZT at the time of HIV-1 challenge. The 
efficiency of activation of latent HIV-1 depended on 
the amount of exosomes used, and appeared strongly 
reduced by treatment with either TAPI-2 or anti-
TNFα Abs at the time of exosome challenge (Fig.  5c, 
d).
These data which were obtained using a system of 
HIV-1 latency based on primary lymphocytes appeared 
fully consistent with the results we had previously 
obtained with U1 cells.
Activation of latent HIV‑1 in primary CD4+ T lymphocytes 
challenged with exosomes purified from HIV‑1 infected 
primary cells
To add further significance to our observations, we repro-
duced the experiments on HIV-1 latently infected CD4+ 
T lymphocytes using exosomes purified from primary 
cells (i.e., CD4+ T lymphocytes and monocyte-derived 
macrophages, MDMs) acutely infected with HIV-1. In 
detail, both PHA-stimulated CD4+ T lymphocytes and 
MDMs were infected with (VSV-G) HIV-1, and, when 
>50  % of cells expressed HIV-1, supernatants were har-
vested and exosomes purified through differential cen-
trifugations. Nanovesicles were loaded on a 6–18  % 
discontinuous gradient and, as here above described, 
those comprised in AchE positive fractions were formally 
identified as exosomes on the basis of the binding with 
CTX-B and the presence of CD63 (Fig. 6a).
HIV-1 latently infected CD4+ T lymphocytes were 
recovered 72 h after virus challenge (Fig. 6b) as described 
above, and treated with 100  μU of exosomes purified 
from either uninfected or HIV-1 productively infected 
CD4+ T lymphocytes and MDMs. We observed HIV-1 
activation within latently infected cells challenged with 
exosomes isolated from infected but not uninfected pri-
mary cell cultures. Virus activation was no more detecta-
ble when target cells were pre-treated with AZT (Fig. 6c), 
its efficiency depended on the size of the exosome input, 
and was basically abolished by the treatment with either 
TAPI-2 or anti-TNFα (Fig.  6d, e). The latter results 
appeared consistent with the detection of activated 
ADAM17 in exosome preparations from infected but not 
uninfected CD4+ T lymphocytes and MDMs (Fig. 6f ).
We concluded that exosomes from HIV-1 infected pri-
mary cells can activate latent HIV-1.
(See figure on next page.)
Fig. 5 HIV-1 latently infecting primary CD4+ T lymphocytes is activated upon challenge with exosomes from HIV-1 infected cells. Untouched CD4+ T 
lymphocytes isolated from PBMCs of four healthy donors were challenged by spinoculation with (VSV-G) ΔenvHIV-1 in the presence or not of AZT. As 
control, conditions with unchallenged CD4+ T lymphocytes (Ctrl) were included. After 48 h, cells were extensively washed and then left in culture for 
additional 24 h. a Intracytoplasmic CAp24 FACS analysis of CD4+ T lymphocytes 72 h post-infection. The results are the mean values + SD calculated 
after challenge of CD4+ T lymphocytes from four healthy donors in duplicate conditions. b Intracytoplasmic CAp24 FACS analysis of HIV-1 latently 
infected CD4+ T lymphocytes 24 h after spinoculation with 100 μU of exosomes purified from either uninfected U937 cells or their counterpart 
chronically infected with ΔnefHIV-1 and expressing or not wt Nef. As control, cells were treated with 10 ng/mL of PMA+ 0.5 μg/μL of ionomycin 
(PMA) or left untreated (Ctrl). In addition, CD4+ T lymphocytes originally challenged with (VSV-G) ΔenvHIV-1 in the presence of AZT were treated 
with either PMA + ionomycin or exosomes from HIV-1 infected U937 cells expressing wt Nef. Shown are the results calculated as mean percentage 
values of triplicate cultures of CD4+ T lymphocytes from each donor. The inter-donor mean values + SD are also presented. *p < 0.05. The same 
experiments whose data are shown on panels a and b have been reproduced using PBMCs from two healthy donors and three doses (from 10 to 
100 μU) of exosomes from cells infected with ΔnefHIV-1 and expressing wt Nef. In addition, CD4+ T quiescent lymphocytes challenged with 100 μU 
of exosomes were treated with either TAPI-2, anti-TNFα Abs, or isotype matched IgGs soon after the exosome challenge. c Intracytoplasmic CAp24 
FACS analysis of CD4+ T lymphocytes 72 h post-infection. The results are the mean values + SD calculated after challenge of CD4+ T lymphocytes 
from two healthy donors in duplicate conditions. d Intracytoplasmic CAp24 FACS analysis of HIV-1 latently infected CD4+ T lymphocytes 24 h after 
spinoculation with the exosomes. As control, cells were treated with 10 ng/mL of PMA+ 0.5 μg/μL of ionomycin (PMA) or left untreated (Ctrl). In 
addition, CD4+ T lymphocytes originally challenged with (VSV-G) ΔenvHIV-1 in the presence of AZT were treated with either PMA+ ionomycin or 
exosomes. Shown are the results calculated as mean percentage values of duplicate cultures of CD4+ T lymphocytes from each donor
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Activation of latent HIV‑1 in primary CD4+ T lymphocytes 
upon co‑cultivation with autologous CD4+ T lymphocytes 
productively infected with HIV‑1
Transfer of exosomes from HIV-1 infected cells to HIV-1 
latent reservoir is expected to be accompanied by trans-
mission of additional nano- and microvesicles (including 
HIV-1 particles), as well as soluble factors. To better evalu-
ate the potential role of additional extra-cellular factors in 
the exosome-induced activation of latent HIV-1, we set 
up trans-well co-cultures of HIV-1 productively infected 
cells with HIV-1 latently infected CD4+ T lymphocytes. 
In detail, CD4+ T lymphocytes were infected with (VSV-
G) HIV-1 2 days after PHA-stimulation, and, at the peak 
of HIV-1 replication, put in the upper chamber of a trans-
well plate in the absence of exogenous cell activation fac-
tors, such as PHA, IL-2. In the lower chamber, autologous 
HIV-1 latently infected CD4+ T lymphocytes were seeded. 
Controls in the upper chamber included uninfected acti-
vated CD4+ T lymphocytes, whereas in the lower cham-
ber comprehended resting CD4+ T lymphocytes either 
uninfected or treated with AZT at the time of infection. 
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Fig. 6 Exosomes from HIV-1 productively infected primary cells activates latent HIV-1 infecting primary CD4+ T lymphocytes. Untouched CD4+ T 
lymphocytes from PBMCs of healthy donors were challenged by spinoculation with (VSV-G) ΔenvHIV-1 in the presence or not of AZT. As a control, 
conditions with unchallenged CD4+ T lymphocytes (Ctrl) were included. After 48 h, cells were extensively washed, and then left in culture for 
additional 24 h. Afterwards, exosome challenge was performed as described below. a FACS analysis for the presence of both GM1 and CD63 in nan-
ovesicles recovered from pools of AchE positive fractions of iodixanol gradients loaded with nanovesicle pellets from supernatants of either CD4+ T 
lymphocytes or MDMs infected with (VSV-G) wtHIV-1. Vesicles were bound to aldehyde/sulfate latex beads and then labeled with FITC-conjugated 
CTX-B and PE-conjugated anti-CD63 mAb. b Intracytoplasmic CAp24 FACS analysis of CD4+ T lymphocytes 72 h post-infection. The results are 
expressed as mean HIV-1 Gag+ percentage calculated after challenge of CD4+ T lymphocytes from three healthy donors analyzed in duplicate 
conditions. c Intracytoplasmic CAp24 FACS analysis of HIV-1 latently infected CD4+ T lymphocytes 24 h after spinoculation with 100 μU of exosomes 
purified from HIV-1 infected CD4+ T lymphocytes or MDMs. As a control, the cells were challenged with equivalent amounts of exosomes from 
uninfected CD4+ T lymphocytes or MDMs. CD4+ T lymphocytes were also treated with PMA + ionomycin (PMA) or left untreated (Ctrl). In addition, 
CD4+ T lymphocytes originally challenged with (VSV-G) ΔenvHIV-1 in the presence of AZT were treated with either PMA + ionomycin or exosomes 
from HIV-1 infected cells, i.e. CD4+ T lymphocytes and MDMs. The results are reported as mean percentage values + SD of duplicate cultures of 
CD4+ T lymphocytes from three healthy donors. *p < 0.05. The same experiment whose results are shown in the panel C has been conducted with 
CD4+ T lymphocytes from two healthy donors which were latently infected with ΔenvHIV-1 in the presence or not of AZT. Panel d reports the mean 
percentage values of HIV-1 expressing cells 72 h after challenge. Then, cells were challenged with three doses of each exosome preparation, i.e., 
from 10 to 100 μU, or with PMA as a control. In addition, cell challenged with 100 μU of exosomes were treated with either TAPI-2, anti-TNFα Abs, or 
isotype matched IgGs soon after exosome challenge. The results calculated as mean percentage values of duplicate cultures of CD4+ T lympho-
cytes from each donor are shown in panel e, f. ADAM17 activity detected in 1 mU of exosomes purified from the supernatants of both uninfected 
or HIV-1 infected CD4+ T lymphocytes and MDMs. Shown are mean values of ng of active ADAM17 detected in quadruplicate samples from a 
representative exosome preparation from each cell culture
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activation in latently infected CD4+ T lymphocytes was 
evaluated by intracellular HIV-1 Gag FACS analysis. In 
these co-culture experiments the effects of two inhibitors 
of exosome biogenesis (i.e., GW4869 and spiroepoxide) 
[39–43], TAPI-2, and anti-TNFα Abs, as well as the role of 
Nef expression in HIV-1 productively infected cells were 
evaluated. Our data show that (Table 1): (1) activation of 
latent HIV-1 did occur in co-cultures comprising CD4+ 
T lymphocytes productively infected with wtHIV-1; (2) 
activation was no more detectable in the presence of the 
exosome inhibitors; (3) treatment with either TAPI-2 or 
anti-TNFα Abs effectively reduced the number of HIV-
1-expressing cells in latently infected CD4+ T lympho-
cytes, and (4) Nef expression in productively infected 
cells was mandatory for optimal activation of latent HIV-
1. Hence, as previously observed with purified exosomes, 
also in the co-culture system exosomes from HIV-1 
infected cells induced activation of latent HIV-1 through a 
Nef- and ADAM17-dependent way, whereas the presence 
of additional extra-cellular factors appeared ineffective. As 
expected, in the presence of AZT no HIV-1 infected cells 
were found when uninfected, resting CD4+ T lymphocytes 
were used as target cells, thus excluding events of produc-
tive infection due to transmission of HIV-1 from produc-
tively infected cells. Also, transmission of cell-activating 
soluble factors possibly released by productively infected 
and/or activated cells did not seem to interfere with the 
results we obtained since no or very little HIV-1 activa-
tion was seen: (1) in latently infected cells co-cultivated 
with uninfected, activated cells; and (2) in co-cultures 
carried out in the presence of either the exosome inhibi-
tors, TAPI-2, or anti-TNFα Abs, and (3) when effector 
cells were infected with Δnef HIV-1. Finally, as observed 
in our previous experiments, the lack of HIV-1 activation 
in unstimulated CD4+ T lymphocytes treated with AZT 
before infection and co-cultivated with HIV-1 expressing 
cells indicated that the Gag-specific FACS assay detected 
de novo produced intracellular Gag molecules only.
The results from this set of experiments support the 
idea that extra-cellular factors released by HIV produc-
tively infected cells have no major influence on the exo-
some-dependent activation of latent HIV.
Activation of latent HIV‑1 by exosomes from cells infected 
with a non‑producer HIV‑1
The majority of integrated HIV-1 genomes present in 
cART-treated patient is defective [44–48], and, at least in 
part, transcriptionally active [49]. We were interested in 
understanding whether exosomes released by cells express-
ing defective HIV-1 can activate latent HIV-1. To this end, 
we purified exosomes from a cell line, referred to as Hut-78/
F12, chronically infected with a non-producer, full length 
HIV-1 variant. It expresses a complete viral protein pat-
tern comprising a truncated Vpr, an uncleaved Env gp160 
[50], and a mutated Nef which retains the domain involved 
in the uploading of activated ADAM17 in exosomes [14]. 
As a control, exosomes from parental Hut-78 cells were 
used. The effects of exosomes from the two cell lines were 
Table 1 HIV-1 latently infecting primary CD4+ T lymphocytes is activated upon co-culture with HIV-1 infected autologous 
lymphocytes in both ADAM17- and Nef-dependent ways
CD4+  T lymphocytes were activated, infected with the indicated VSV-G psedotyped HIV-1 strains and, after 3 days, put in the upper chamber of a trans-well plate in 
the presence or not of the indicated inhibitors. As a control, activated, uninfected cells (Ctrl) were also assayed. In the third left column, shown are the percentages of 
HIV-1 expressing cells 3 days after infection as means of duplicates. Infected lymphocyte cultures were then put in separate trans-well co-cultures where in the lower 
chamber autologous resting CD4+ T lymphocytes were seeded 72 h after challenge with Δenv HIV-1 in the absence or presence of AZT. As a control, mock infected 
cells were also seeded. Percentages of HIV-1 Gag expressing cells were scored after 48 h of co-cultivation in the presence of AZT. Shown are the percentages of HIV-1 
expressing cells as detected by intracytoplasmic CAp24 FACS analysis as means of duplicates of independent experiments performed with PBMCs from the number of 
healthy donors indicated in the first left column
No. of donors  
assayed
Effector cells  
in upper chambers
Effector cells:  % 




Target cells in lower chambers: % 
of CAp24+ cells after 2 days of co‑culture
Mock ΔenvHIV‑1 ΔenvHIV‑1
+AZT
5 Ctrl <0.1 Complete medium <0.1 <0.1 <0.1
5 wtHIV-1 31.2 Complete medium <0.1 8.7 <0.1
5 wtHIV-1 32 GW4869+
Spiroepoxide
<0.1 1.6 0.4
3 wtHIV-1 30.9 TAPI-2 0.2 1.8 0.3
2 wtHIV-1 26.4 IgGs 0.2 6.9 0.3
2 wtHIV-1 28.7 Anti-TNFα Abs 0.2 0.2 <0.1
1 ΔnefHIV-1 34.7 Complete medium 0.5 1.8 0.6
1 ΔnefHIV-1 31.3 GW4869+
Spiroepoxide
0.3 0.9 0.3
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analyzed in terms of activation of latent HIV-1 in both U1 
cells and HIV-1 latently infected primary CD4+ T lympho-
cytes. When 120 μU of exosomes from Hut-78/F12 cells 
were used to challenge U1 cells, virus activation become 
readily detectable in terms of release of Gag protein in the 
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Fig. 7 Latent HIV-1 is activated by exosomes from cells infected with defective HIV-1. a A total of 120 μU of exosomes purified from the superna-
tants of either parental Hut-78 or Hut-78/F12 cells were used to challenge 5 × 104 U1 cells in U-bottom 96 well plates. After 24 h, cells were exten-
sively washed, and released HIV-1 was measured as CAp24 concentration in cell supernatants after additional 24 h. As a control, cells were either left 
untreated (Ctrl) or treated with 100 ng/mL of recombinant TNFα. The results are expressed as mean values + SD from six independent experiments 
carried out with duplicates. *p < 0.05. b The same experiment whose data are reported on panel a has been reproduced on U1 treated with either 
TAPI-2, anti-TNFα Abs, or isotype matched IgGs soon after the exosome challenge. Shown are the results calculated as mean values from two experi-
ments with duplicates. c Western blot analysis for the expression of ADAM17 in either Hut-78 or Hut-78/F12 cells. Signals from cellular ADAM17 
were normalized with β-actin signals, whereas exosome preparations were also probed for the presence of ICAM-1. On the left of each panel, molec-
ular weight markers are given in kDa. On the right, arrows identify both inactive and active ADAM17 forms. The results are representative of two 
independent experiments. d Effects of exosomes from Hut-78/F12 cells on HIV-1 latently infecting primary CD4+ T lymphocytes. A total of 5 × 104 
of untouched primary CD4+ T lymphocytes was challenged by spinoculation with (VSV-G) ΔenvHIV-1 in the presence or not of AZT. As a control, 
conditions with unchallenged CD4+ T lymphocytes (Ctrl) were included. After 48 h, HIV-1 latently infected cells were extensively washed and then 
left in culture for additional 24 h. Afterwards, cells were challenged with 120 μU of exosomes from either Hut-78 or Hut-78/F12 cells. Shown are the 
percentages of HIV-1 Gag expressing cells as detected by intracytoplasmic CAp24 FACS analysis 24 h post-exosome challenge. As a control, cells 
were either treated with PMA + ionomycin (PMA), or left untreated (Ctrl). In addition, CD4+ T lymphocytes challenged with (VSV-G) ΔenvHIV-1 in the 
presence of AZT were treated with either PMA + ionomycin or exosomes from either Hut-78 or Hut-78/F12 cells. Shown are the results calculated 
as mean percentage values + SD of triplicate cultures of CD4+ T lymphocytes from three donors. *p < 0.05. e The same experiment whose data are 
reported in panel d has been reproduced using CD4+ T lymphocytes treated with either TAPI-2, anti-TNFα Abs, or isotype matched IgGs soon after 
exosome challenge. The results are shown as mean percentage values from two experiments with duplicate cultures
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cells proved ineffective (Fig.  7a). The effects of exosomes 
from Hut-78/F12 cells were abolished by treatment with 
either TAPI-2 or anti-TNFα Abs (Fig. 7b), in line with the 
detection of activated ADAM17 in exosomes from Hut-78/
F12 but not Hut-78 cells (Fig. 7c).
Consistently, we observed that treatment with 
exosomes from Hut-78/F12 cells, but not parental Hut-
78, activated latent HIV-1 infecting primary CD4+ T 
lymphocytes (Fig. 7d), and that this effect was abolished 
by both TAPI-2 and anti-TNFα Abs (Fig. 7e).
We concluded that latent HIV-1 can be activated by 
exosomes from cells infected with defective HIV-1. These 
effects may mirror events leading to reservoir activation 
possibly occurring in cART-treated patients, where a rel-
evant part of integrated HIV-1 is both defective and tran-
scriptionally active.
Lack of HIV‑1 replication in activated CD4+ T lymphocytes 
challenged with exosomes purified from HIV‑1 infected 
cells
We here provide evidence that HIV-1 latently infect-
ing CD4+ T lymphocytes can be activated by the treat-
ment with exosomes from cells infected with HIV-1 
expressing a functional Nef. Because HIV-1 infectivity 
can be enhanced by exosomes [51], we took particular 
care in ruling out the presence of HIV-1 infectious par-
ticles contaminating our exosome preparations which 
might have contributed to HIV-1 replication detected in 
HIV-1 latently infected cells challenged with exosomes. 
To assess the presence of infectious HIV-1 in the exo-
some preparations, 5  ×  104 PHA-activated primary 
CD4+ T lymphocytes (i.e., the same number of HIV-1 
latently infected cells we used for exosome treatments) 
were challenged by spinoculation with the largest vol-
umes of each exosome preparation we used for experi-
ments on HIV-1 latently infected cells. As a control, cells 
were infected with 50  pg CAp24 equivalents of HIV-
1. Twenty-four hours later, the cells were extensively 
washed and the cultures monitored for HIV-1 replica-
tion in terms of both CAp24 release in supernatants and 
intracellular CAp24 cell expression until 7  days after 
challenge. As shown in Table  2, no evidence of HIV-1 
infection was found in all cell cultures challenged with 
the various exosome preparations. The rather low levels 
of CAp24 detected in some instances in supernatants at 
the earliest day post infection most likely reflected the 
presence of residual exosome vesicles which, as already 
described, can incorporate HIV-1 Gag molecules when 
produced by HIV-1 infected cells [9, 14]. Accordingly, 
similar results were observed by pre-treating target cells 
with AZT (not shown).
Even though it is basically impossible to rule out the 
presence of minimal amounts of infectious viral particles 
contaminating our exosome preparations, we concluded 
that the HIV-1 expressing cells we detected in HIV-1 
latently infected cells 24  h after exosome challenge did 
not originate from the infection with contaminating 
infectious HIV-1 particles.
Discussion
Cells infected with either replication-competent or 
defective HIV-1 release exosomes uploading activated 
ADAM17 [14, 15]. These “armed” nanovesicles induce 
cell activation in target quiescent CD4+ T lymphocytes 
which then become susceptible to HIV replication. By 
extending the investigations to HIV-1 latent infection, 
we observed that exosomes from HIV-1 infected cells 
activate the HIV-1 latently infecting U1 cells. Virus acti-
vation relies on both uploading of activated ADAM17 
in exosomes and release of TNFα from target cells. 
The results we obtained using HIV-1 strains deleted or 
mutated in nef are consistent with our previous findings 
[15], hence further enforcing the idea that the upload-
ing of activated ADAM17 in exosomes depends on the 
expression of Nef in exosome-producing cells. On the 
other hand, we had no evidences suggesting the involve-
ment of exosome-associated Nef in the activation of 
latent HIV-1.
Apparently uninfected small sub-populations were 
detectable within HIV-1 infected U937 cells we used 
as exosome source. Since it is known that the expres-
sion of Nef in exosome-producing cells is sufficient for 
the uploading of activated ADAM17 in exosomes [15], 
the presence of these cells lacking HIV-1 expression but 
actually expressing Nef was not expected to influence the 
downstream results.
Many protocols to recover HIV-1 latently infected cells 
have been developed and recently compared in a quite 
comprehensive study [38]. We developed a system basi-
cally similar to that described by Greene’s group [31]. 
Key experimental points consist in leaving CD4+ T lym-
phocytes untouched during the immunomagnetic selec-
tion from PBMCs, and challenging them with (VSV-G) 
Δenv HIV-1. The use of this viral strain guaranteed opti-
mal levels of viral entry in target cells meanwhile avoid-
ing, when latent HIV-1 is activated, re-infection events 
potentially biasing the interpretation of results. The over-
all efficiency of infection we detected after cell activation 
(3–6 % of HIV-1 expressing cells) appeared fully consist-
ent with that previously reported using different HIV-1 
derivatives [2, 31].
In a quite similar system of HIV-1 latency, exogenous 
TNFα was shown to activate latent HIV-1 with a very low 
efficiency [31]. Consistently, in the here described trans-
well co-cultures where activated donor lymphocytes 
were expected to release TNFα, no apparent activation 
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of latent HIV-1 occurred in the presence of inhibitors of 
exosome release. Most likely, additional molecular events 
besides the release of TNFα from target cells are neces-
sary for the activation of latent HIV-1. Exact delineation 
of the mechanisms underlying the exosome-induced acti-
vation of HIV latency requires additional investigations.
We can exclude that the activation of latent HIV-1 
we observed in the different cell/exosome systems used 
depended on the presence of infectious HIV-1 particles con-
taminating the exosome preparations. In fact, when cells 
most susceptible to HIV infection, i.e., activated primary 
CD4+ T lymphocytes, were challenged with our exosome 
preparations, no viral replication was detectable. These data 
were obtained in experimental conditions much more strin-
gent than those used in the HIV-1 latency assays, i.e., using 
activated rather than resting CD4+ T lymphocyte target cells, 
and prolonging the observation period to 7 days instead of 
the 24 h incubation we considered after exosome treatment.
The high mutation rate occurring in HIV-1 retrotran-
scription leads to the emergence of defective HIV-1 
genomes which can persist in blood cells of HIV-1 
infected patients. These cells are expected to have a 
longer life span than cells infected with replication-com-
petent quasispecies as a consequence of the attenuated 
cytotoxicity of mutated viral products [45]. The pres-
ence of a relevant burden of defective HIV-1 genomes 
integrated in PBMCs of infected patients was demon-
strated in both PBMCs and rectal tissues of cART-treated 
patients [46]. It was estimated that the percentage of 
defective HIV-1 genomes in viral reservoirs of treated 
patients overrides that of replication-competent ones by 
more than 100-folds [48]. This hypothesis was also sup-
ported by the evidence that treatment of HIV-1 reser-
voirs with various cell activation factors invariably led 
to virus release from only a minority of cells integrating 
HIV-1 [47]. Hence, investigating whether activation of 
latent HIV-1 can also occur when exosome-producing 
cells are infected with defective HIV-1 is of relevance. 
Here, we provide evidence that exosomes released by 
cells infected with defective HIV-1 can induce activation 
of latent HIV-1. In infected patients, any defective but 
transcriptionally active HIV strain would be part of this 
mechanism whatever their mutations/deletions, except 
those inactivating either Tat or the Nef domain involved 
in the uploading of ADAM17 in exosomes.
Whether or not cART totally halts virus replication 
is still under debate. In the case of a complete block of 
HIV-1 replication, exosome-dependent reactivation of 
latent HIV-1 would lead to a progressive depletion of the 
latent reservoir due to both cell death of virus-express-
ing cells and immune surveillance. In contrast, when 
cART leakiness occurs to some extent, exosomes from 
cells infected with defective HIV-1 strains (insensitive to 
cART) may contribute to the re-activation of the latent 
reservoir leading to the episodes of transient viremia 
(“blips”) occurring in cART treated patients [52–55].
Conclusions
The presence of latent reservoirs is a major hurdle 
towards HIV eradication. Hence, the study of mecha-
nisms underlying activation and transmission of latent 
HIV infection is relevant not only to clarify still unknown 
Table 2 Lack of HIV-1 replication in PHA-activated CD4+T lymphocytes challenged with different exosome preparations
A total of 5 × 104  CD4+ T lymphocytes were spinoculated with 120 μU of the exosome preparations indicated in the left column. As a control, the same number of 
cells was challenged with 50 pg CAp24 equivalents of the T-tropic NL4-3 HIV-1 strain. Cell cultures were washed 24 h later, and viral replication was monitored at the 
indicated days post-infection by measuring CAp24 levels in supernatants as well as scoring HIV-1 expressing cells by CAp24 FACS analysis. Shown are mean values 
obtained by challenging cells from two healthy donors with duplicate conditions
Days post‑challenge input CAp24 pg/ml % of HIV‑1+ cells
2 5 7 2 5 7
Exo U937 <15 <15 <15 <1 <1 <1
Exo U937 Δnef HIV-1 31 <15 <15 <1 <1 <1
Exo U937 Δnef
HIV-1 + wtNef
26 <15 <15 <1 <1 <1
Exo U937 Δnef
HIV-1 + NefG2A
44 <15 <15 <1 <1 <1
Exo CD4+ T lymphocytes <15 <15 <15 <1 <1 <1
Exo CD4+ T lymphocytes + HIV-1 <15 <15 <15 <1 <1 <1
Exo MDMs <15 <15 <15 <1 <1 <1
Exo MDMs + HIV-1 <15 <15 <15 <1 <1 <1
Exo Hut-78 <15 <15 <15 <1 <1 <1
Exo Hut-78/F12 89 <15 <15 <1 <1 <1
HIV-1, 50 pg <15 9980 2400 <1 32.2 7.9
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aspects of HIV pathogenesis, but also to improve the 
therapeutic approaches aimed at virus eradication. Here, 
we provide evidence that latent HIV-1 can be activated 
by exosomes released by HIV-1 infected cells. This event 
is mediated by the activity of ADAM17 uploaded in 




U1, U937 cells and derivatives thereof, Hut-78, Hut-78/
F12 [50] were grown in RPMI medium plus 10  % heat-
inactivated fetal calf serum (FCS). Human embry-
onic kidney 293T cells were grown in Dulbecco’s 
modified Eagle’s medium plus 10  % heat-inactivated 
fetal calf serum (FCS). CD4+ T lymphocytes were iso-
lated from PBMCs of healthy donors by negative selec-
tion using an immunomagnetic-based kit (Miltenyi), and 
cultivated in RPMI medium plus 10 % FCS. Cell cultures 
were checked for purity through FACS analysis for CD4, 
CD8, and CD14 markers. Cell preparations having more 
than 3 % of CD8+ cells and/or 1 % of CD14+ cells were 
discarded. For cell activation, either 10  ng/mL of PMA 
plus 0.5  μg/mL of ionomycin or 2  μg/mL of PHA were 
added to CD4+ T lymphocyte cultures. Monocytes were 
isolated from PBMC of healthy donors using an immu-
nomagnetic monocyte selection kit (Miltenyi). Purity of 
recovered cell populations was assayed by FACS analysis 
using PE-conjugated anti-CD14 mAb (Becton–Dickin-
son). To obtain human primary monocyte-derived mac-
rophages (MDMs), monocytes were cultured for 7  days 
in 48 well plates in RPMI supplemented with 20 % FCS.
For Nef activation, HT from Sigma was solubilized in 
DMSO and used at 50 nM. TAPI-2 was purchased from 
Santa Cruz Biotechnology and used at 1  μM. Recombi-
nant human TNFα was bought from R&D Systems. AZT 
was obtained from NIH AIDS Research and Reference 
Reagent Program, and used at 10  μM. For anti-TNFα 
neutralization experiments, either anti-TNFα neutral-
izing antibodies (polyclonal rabbit antibodies, Fitzgerald 
Industries) or normal rabbit IgGs were added to CD4+ T 
lymphocytes immediately after exosome challenge. The 
same amounts of antibodies were then re-added after 
24 h of culture.
Molecular clones, transfections, and HIV‑1 infections
Preparations of VSV-G pseudotyped HIV-1 were 
obtained from supernatants of 293T cells 48  h after 
transfection with either pNL4-3 HIV-1 molecular 
clone or its Δenv and Δnef derivatives co-transfected 
with a pcDNA3.1 (Invitrogen)-based vector express-
ing VSV-G in 5:1 molar ratio. Transfections were 
performed using Lipofectamine 2000 (Invitrogen). 
Supernatants were clarified and concentrated by 
ultracentrifugation on a 20 % sucrose cushion as pre-
viously described [56]. This method ensured that 
exosomes from transfected cells were excluded from 
the vesicle pellet [57]. Virus preparations were titrated 
in terms of HIV-1 CAp24 content using quantitative 
enzyme-linked immunosorbent assay (ELISA, Innoge-
netic). Infections with HIV-1 were carried out by spi-
noculation at 400×g for 30 min at room temperature 
(r.t.) using 500 ng CAp24 equivalents of HIV-1 for 106 
cells.
Establishment of CD4+ T lymphocyte cultures latently 
infected with HIV‑1
Untouched CD4+ T lymphocytes isolated from PBMCs 
of healthy donors were spinoculated using 300  ng 
CAp24 equivalents of (VSV-G) Δenv HIV-1/106 cells 
in the presence or not of AZT. After 48  h, cell cultures 
were extensively washed and refed. One day later, CD4+ 
T lymphocytes were analyzed for intracytoplasmic con-
tents of HIV-1 Gag products. Cell cultures with more 
than 0.3  % of positive cells for HIV-1 Gag expression 
were discarded. Otherwise, CD4+ T lymphocytes were 
challenged with exosomes or put in trans-well co-cul-
tures, and HIV-1 expression was evaluated after addi-
tional 24-48 h.
Trans‑well co‑cultures
Trans-well co-cultures were carried out in 12-well plates 
using Cell Culture Insert Falcon Membrane (25  mm 
diameter, 0.4 μm pore size, Becton–Dickinson). For prep-
aration of exosome-donor cells, CD4+ T lymphocytes 
were activated for 48 h, and then infected with spinocula-
tion with 200 ng CAp24 equivalents of (VSV-G) wtHIV-
1/106 cells or equivalent amounts of the Δnef derivative. 
After additional 72  h, the percentage of HIV-1 infected 
cells was evaluated by Gag-specific FACS analysis. In the 
presence of at least 25  % of infected cells, cell cultures 
were seeded in the upper chamber of trans-well plates 
while HIV-1 latently infected autologous CD4+ T lym-
phocytes obtained as described above were seeded in the 
bottom chamber. AZT was then added to the co-cultures 
which were run for 48 h in the presence or not of 1 μM 
of either GW4869 (Sigma) and spiroepoxide (Santa Cruz) 
inhibitors of exosome synthesis [39–43], TAPI-2 [30], or 
anti-TNFα Abs. Thereafter, target lymphocytes seeded 
in the bottom chambers were analyzed by FACS for the 
expression of intracytoplasmic HIV-1 CAp24.
Nanovesicle purification and challenge
Cell culture supernatants containing exosome-depleted 
FCS were processed following already described methods 
for exosome purification [58, 59]. In detail, supernatants 
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were centrifuged at 500×g for 10 min. Then, the super-
natants underwent differential centrifugations consist-
ing in a first ultracentrifugation at 10,000×g for 30 min. 
Supernatants were then harvested, filtered with 0.2  μM 
pore size, and ultracentrifuged at 70,000×g for l  h. The 
pelleted vesicles were washed in 1  ×  PBS, and ultra-
centrifuged again at 70,000×g for 1  h. Afterwards, the 
pellet was resuspended in 200–400  µL of 1 ×  PBS and 
subjected to discontinuous iodixanol (Axis-Shield) gra-
dient. Briefly, concentrated vesicles were ultracentri-
fuged at 200,000×g for 1.5 h at 4 °C in an SW41 Ti rotor 
(Beckman) through a 6–18 % iodixanol density gradient 
formed by layering iodixanol in 1.2 % increments. Then, 
0.7 mL fractions were collected starting from the top. In 
some instances, half of each fraction was diluted with 2 
volumes of 0.9  % sodium chloride and ultracentrifuged 
for 30 min at 95,000 rpm in a TL-100 tabletop ultracen-
trifuge. Finally, the pellet was resuspended in 50  µL of 
Tris–HCl pH 7.4 10 mM, NaCl 100 mM, EDTA 1 mM. 
A total of 5 × 104 cells/condition was used for exosome 
challenges which were performed by spinoculation as 
described for HIV-1 infection.
Detection of AchE, ADAM17 and TNFα contents 
in exosomes
Vesicle-associated AchE activity was evaluated through 
Amplex Red kit (Molecular Probes) following the man-
ufacturer’s recommendations. The AchE activity was 
measured as mU/mL, where 1  mU is defined as the 
amount of enzyme which hydrolyzes 1  pmol of acetyl-
choline to choline and acetate per minute at pH 8.0 at 
37 °C. The activity of exosome-associated ADAM17 was 
assayed through the Innozyme TACE activity kit (Calbio-
chem) which was carried out on 1 mU equivalent of AchE 
activity of each exosome preparation following the man-
ufacturer’s recommendations. Measurement of TNFα in 
the exosome preparations was performed through ELISA 
kit from Immunological Sciences following the manufac-
turer’s recommendations.
FACS analysis of cells and nanovesicles
To detect intracytoplasmic HIV-1 CAp24, cells were 
treated with trypsin for 15 min at 37 °C. Then, they were 
labeled using the KC57-RD anti-CAp24 monoclonal 
antibody (Coulter) upon permeabilization with Cyto-
fix/Cytoperm solutions (BD Pharmingen) as previously 
described [56]. HIV-1 Gag and Nef double staining was 
performed by permeabilizing cells in a similar way, and 
then incubating them with the anti-Nef MATG mAb 
(generous gift of O. Schwartz, Institute Pasteur, Paris, 
France). Cells were then labeled with FITC-conjugated 
anti-mouse IgG Abs, and finally with the KC57-RD anti-
CAp24 mAb.
Double staining of nanovesicles was performed by 
incubating them with 5  µL of surfactant-free white 
aldehyde/sulfate latex beads overnight at r.t. on a rotat-
ing plate. Afterwards, nanovesicle-bead complexes were 
washed and incubated at 37 °C for 2 h with FITC-conju-
gated cholera toxin, subunit B (CTX-B) for GM1 detec-
tion. Then, the samples were washed and incubated with 
PE-conjugated anti-CD63 monoclonal antibody (BD 
Pharmingen) 1 h at 37 °C. Finally, the beads were washed, 
resuspended in 1 × PBS-2 % v/v formaldehyde, and FACS 
analyzed.
Western blot assay
Western blot analysis on cell lysates was performed 
by washing cells twice with 1 × PBS (pH 7.4) and lys-
ing them for 20  min on ice with lysis buffer (20  mM 
HEPES pH 7.9, 50  mM NaCl, 10  mM EDTA, 2  mM 
EGTA, 0.5  % nonionic detergent IGEPAL CA-630, 
0.5  mM dithiothreitol, 20  mM sodium molybdate, 
10  mM sodium orthovanadate, 100  mM sodium fluo-
ride, 10  μg/mL leupeptin, 0.5  mM phenylmethylsul-
fonyl fluoride). Whole cell lysates were centrifuged 
at 6000×g for 10  min at 4  °C. Protein concentration 
of cell extracts was determined by the Lowry protein 
quantitation assay. Aliquots of cell extracts contain-
ing 30–50  μg of total proteins were resolved by 12  % 
sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred by electroblot-
ting on a 0.45  μm pore size nitrocellulose membrane 
(Amersham) overnight using a Bio-Rad Trans-Blot. 
Antibodies used in immunoblots were: pools of 
strongly HIV-1 positive human sera, sheep polyclonal 
anti-Nef ARP444 (a generous gift from Dr. Mark Har-
ris), rabbit polyclonal anti-ADAM17 from Cell Sign-
aling, and monoclonal anti-β-actin AC-74 (Sigma). 
Immune complexes were detected with horserad-
ish peroxidase-conjugated secondary antibodies (GE 
Healthcare) and enhanced chemiluminescence reac-
tion (Euroclone).
Statistical analysis
When appropriate, data are presented as mean + stand-
ard deviation (SD). In some instances, the paired 
Student’s t Test was used and confirmed using the non-
parametric Wilcoxon rank sum test. P < 0.05 was consid-
ered significant.
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